Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 4, 2002, Pages 102-109

  Gandara, David R ^a   Lara Jr, Primo N ^a   Goldberg, Zelanna ^a   Le, Quynh T ^a   Mack, Phillip C ^a   Lau, Derick H M ^a   Gumerlock, Paul H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYTOTOXIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE; TIRAPAZAMINE;

ANGIOGENESIS; ANIMAL CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TOLERABILITY; GENE MUTATION; HEARING LOSS; HUMAN; HYPOXIC CELL; LUNG NON SMALL CELL CANCER; METASTASIS; MUSCLE CRAMP; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VOMITING;

EID: 0036121220     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31531     Document Type: Article

References (49)

1. The histological structure of some human lung cancers and the possible implications for radiotherapy
2. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
3. The proportion of hypoxic cells in a human tumor
4. Tissue oxygen distribution in head and neck cancer patients
5. 2 tension measurements
6. 2 tension measurements
7. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity
8. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
9. Pretreatment of oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
10. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
11. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
12. Hypoxia causes the activation of nuclear factor κB through the phosphorylation of 1κBα on tyrosine residues
13. Activation of AP-1 and of a nuclear redox factor, Ref- 1, in the response of HT29 colon cancer cells to hypoxia
14. Hypoxia-associated induction of early growth response- 1 gene expression
15. 2 homeostasis
16. Hypoxia response elements
17. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
18. Genetic instability induced by the tumor microenvironment
19. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
20. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis
21. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
22. Candidate genes for the hypoxic tumor phenotype
23. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
24. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies
25. Vascular endothelial growth factor expression is increased in renal cell carcinoma
26. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
27. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
28. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma
29. Metallothionein IIA is up-regulated by hypoxia in human A431 squamous carcinoma cells
30. The hypoxic tumor cell: A target for selective cancer chemotherapy
31. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
32. Intranuclear metabolism of tirapazamine by matrix-associated reductases
33. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
34. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo
35. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells
36. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation
37. Enhancement of alkyiating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma
38. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin
39. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin
40. A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC)
41. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study
42. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
43. Comparison of tirazone (tirapazamine) and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international phase III CATAPULT II Trial
44. Phase II study of the combination of vinorelbine, cisplatin, and tirapazamine in advanced non-small cell lung cancer
45. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
46. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial
47. Tirapazamine (TPZ) plus taxol]carboplatin (Carbo): A California Cancer Consortium phase 1 trial and implications for SWOG 0003
48. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas. A phase II study
49. Phase 1 trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer